Protocol Title: A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

Sponsor: Black Diamond Therapeutics, Inc.
CRO: IQVIA Biotech

Version 3.0
Dated August 25-2022

Any questions regarding this manual can be directed to your CRA or Black Diamond Therapeutics, Inc. Please refer to the study contact list provided in the Site Regulatory Binder.

WARNINGS:

This manual is specific to dose preparation of the investigational medicinal product (IP), BDTX-1535, to be used in study BDTX-1535-101.

Study sites cannot transfer or receive IP to/from another study site.
**DOCUMENT HISTORY**

<table>
<thead>
<tr>
<th>Version</th>
<th>Version Date</th>
<th>Summary of Key Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>02-Dec-21</td>
<td>Original</td>
</tr>
<tr>
<td>2.0</td>
<td>18-Feb-22</td>
<td>Added Investigational Product Accountability Log; Removed DRIVE</td>
</tr>
<tr>
<td>3.0</td>
<td>26-Feb-22</td>
<td>Added details on 100 mg. Added details for S. Korean site management of IP</td>
</tr>
</tbody>
</table>
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRA</td>
<td>Clinical Research Associate</td>
</tr>
<tr>
<td>CRO</td>
<td>Contract Research Organization</td>
</tr>
<tr>
<td>DOF</td>
<td>Drug Order Form</td>
</tr>
<tr>
<td>FIFO</td>
<td>First In, First Out</td>
</tr>
<tr>
<td>IP</td>
<td>Investigational Product</td>
</tr>
<tr>
<td>RMV</td>
<td>Routine Monitoring Visit</td>
</tr>
<tr>
<td>SIV</td>
<td>Site Initiation Visit</td>
</tr>
<tr>
<td>TE</td>
<td>Temperature Excursion</td>
</tr>
</tbody>
</table>
1. DESCRIPTION

BDTX-1535 is an orally available, highly potent, selective, irreversible inhibitor of allosteric EGFR mutations, including extracellular variants, and amplifications commonly expressed in GBM. In addition, BDTX-1535 inhibits the uncommon EGFR mutations found in NSCLC as well as EGFR C797S mutation which is acquired following 3rd generation EGFR inhibitor therapy. Further details regarding the IP are provided in the BDTX-1535 Investigator’s Brochure.

Note For Temozolomide Cohort Only: Temozolomide will be obtained by sites as commercially available drug product. The package insert and institutional regulations/policies should be followed for resupply, storage, dispensation, and destruction. The Pharmacy Manual does not include additional details about Temozolomide prescribing, administration, or dosing.

2. PACKAGING AND LABELING

Table 1: BDTX-1535 Drug Product

<table>
<thead>
<tr>
<th>Investigational Product</th>
<th>Strength &amp; Dosage Form</th>
<th># Capsules per Bottle</th>
<th>Capsule Picture</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDTX-1535 (Yellow Label)</td>
<td>5 mg White capsule (size 4)</td>
<td>30</td>
<td><img src="image" alt="5 mg Capsules" /></td>
<td>BDTX</td>
</tr>
<tr>
<td>BDTX-1535 (Green Label)</td>
<td>25 mg Orange capsule (size 4)</td>
<td>30</td>
<td><img src="image" alt="25 mg Capsules" /></td>
<td>BDTX</td>
</tr>
<tr>
<td>BDTX-1535 (Blue Label)</td>
<td>100 mg white Capsule (size 0)</td>
<td>30</td>
<td><img src="image" alt="100 mg Capsules" /></td>
<td>BDTX</td>
</tr>
</tbody>
</table>

BDTX = Black Diamond Therapeutics, Inc.

Table 2: BDTX-1535 Label (USA)

Each bottle will be clearly labeled, printed with black writing, according to country specific regulations. This will include but is not limited to sponsor name, protocol number, lot number, storage conditions, and expiration date. The bottle label will vary based on the dose strength. Please see below an example of each of the bottle labels.
Figure 1: 5 mg US Label Proof

BDTX-1535 5 mg Capsules
Store at 36°F - 46°F (2 - 8°C)
Dosage: To Be Taken as Instructed by Investigator
Caution: New Drug - Limited by Federal
(or United States) Law to Investigational Use
For Oral Use Only Keep out of reach of Children
Sponsor: Black Diamond Therapeutics Inc
10th Floor, One Main Street, Cambridge, MA 02142
Phone: 1-617.252.0848

Protocol: BDTX-1535-101
Bottle Number: AA-XXXXX
Lot Number: XXXXXXXX
Investigator Site No.
Patient No.
Each bottle contains XX capsules

Figure 2: 25 mg US Label Proof

BDTX-1535 25 mg Capsules
Store at 36°F - 46°F (2 - 8°C)
Dosage: To Be Taken as Instructed by Investigator
Caution: New Drug - Limited by Federal
(or United States) Law to Investigational Use
For Oral Use Only Keep out of reach of Children
Sponsor: Black Diamond Therapeutics Inc
10th Floor, One Main Street, Cambridge, MA 02142
Phone: 1-617.252.0848

Protocol: BDTX-1535-101
Bottle Number: AA-XXXXX
Lot Number: XXXXXXXX
Investigator Site No.
Patient No.
Each bottle contains XX capsules

Figure 3: 100 mg US Label Proof

BDTX-1535 100 mg Capsules
Store at 36°F - 46°F (2 - 8°C)
Dosage: To Be Taken as Instructed by Investigator
Caution: New Drug - Limited by Federal
(or United States) Law to Investigational Use
For Oral Use Only Keep out of reach of Children
Sponsor: Black Diamond Therapeutics Inc
10th Floor, One Main Street, Cambridge, MA 02142
Phone: 1-617.252.0848

Protocol: BDTX-1535-101
Bottle Number: AA-XXXXX
Lot Number: XXXXXXXX
Investigator Site No.
Patient No.
Each bottle contains XX capsules

Figure 4: 25 mg Global Booklet Label Proof

BDTX-1535 25 mg Capsules
Sponsor: Black Diamond Therapeutics Inc
10th Floor, One Main Street,
Cambridge, MA 02142, USA
Phone: 1-617.252.0848

Protocol: BDTX-1535-101
© AA-XXXXX
© XXXXXXXX
© YYYY-MM-DD
© 
© XX capsules

Figure 5: 100mg Global Label Proof

BDTX-1535 100 mg Capsules
Sponsor: Black Diamond Therapeutics Inc
10th Floor, One Main Street,
Cambridge, MA 02142, USA
Phone: 1-617.252.0848

Protocol: BDTX-1535-101
© AA-XXXXX
© XXXXXXXX
© YYYY-MM-DD
© 
© XX capsules
3. **INITIAL SHIPMENT AND RESUPPLY**

BDTX-1535 will be shipped by PCI Pharma Services in the United States and by Zuellig Pharma in S. Korea to the clinical study sites at 2-8 °C (36-46 °F). The shipment will be in an insulated shipper with a temperature monitor to ensure the temperature was maintained during the transit from the depot to the site.
3.1. Initial Supply

Once your site’s regulatory package is complete and approved, Black Diamond Therapeutics will place a request for your initial IP shipment. All efforts will be made to ship initial IP prior to the SIV.

3.2. Resupply

3.2.1. Resupply Requests
Re-supply is managed by the site and requests are placed via email using Appendix 1: IP Request Form Template for the US order and Appendix 2: IP Request Form S. Korea Template.

**IP resupply requests should be made at least 5 business days before the IP is needed** on site to allow for processing, shipping, and delays. The Pharmacist should be diligent to ensure that sufficient IP is on site to cover any patient treatment until IP can be resupplied. To ensure continuity of supply, the site should request at least 3-cycles of supply or more at the time of request.

<table>
<thead>
<tr>
<th>Table 3: BDTX-1535 Typical Shipping Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Order Placed by 5 pm EST</strong></td>
</tr>
<tr>
<td>Monday</td>
</tr>
<tr>
<td>Tuesday</td>
</tr>
<tr>
<td>Wednesday</td>
</tr>
<tr>
<td>Thursday</td>
</tr>
<tr>
<td>Friday</td>
</tr>
<tr>
<td>Friday (after 5 pm EST)</td>
</tr>
</tbody>
</table>

Note: Expedited same day shipment requests must be received before 12:00pm ET.

<table>
<thead>
<tr>
<th>Table 4: BDTX-1535 Typical Shipping Schedule for South Korea</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1(a). Order received cut-off time</strong></td>
</tr>
<tr>
<td>Business days from Mondays to Fridays (Local time)</td>
</tr>
<tr>
<td>Before 12pm</td>
</tr>
<tr>
<td>After 12pm</td>
</tr>
</tbody>
</table>
4. RECEIPT

Upon receipt of the IP, the pharmacist or designee, should:

- Inspect the shipment (i.e., unpack IP, visually inspect for damage, verify quantity matches packing slip, and download TempTale data)
  - If received in good order, immediately store at 2-8°C (36-46°F) in a secure, locked, limited access location.
  - If a visible alarm bell icon is present on the TempTale (temperature excursion) or the TempTale is not working, place the bottles in quarantine and complete the Temperature Excursion Report Form (See Appendix 2: IP Temperature Excursion Report).

- Acknowledge the shipment via the paper slip received and update the Accountability Log (Appendix 4: Investigational Product Accountability Log).
  - Note – site templates may be used for tracking site/subject inventory as long as all required fields are present.

4.1. Instructions for Handling the Temperature Recorders, Unpacking, and Storing of the IP

1. Open the outer shipping container and remove packing list and other documents.
2. Remove the gel packs surrounding the inner core package (the corrugated carton containing the IP and the TempTale).
3. Remove and open the inner core pack to remove the IP.
4. Remove the TempTale data logger from the box and follow instructions.
5. Hold down the stop button (the red label on the monitor) for three seconds until you see the stop icon on the LCD that confirms that the monitor has been stopped. The stop button may respond immediately if the KEY Delay feature is unchecked in the General Configuration dialog box.
6. When the monitor is stopped, the Sunshine icon will disappear, and the Stop icon will appear if the shipment has arrived in acceptable condition. **NOTE:** When the memory of a TempTale is full, the monitor will stop on its own and the Stop icon will appear in the LCD.
7. If a visible alarm bell icon is present (temperature excursion) or the TempTale is not working, place the bottles in quarantine and complete the Temperature Excursion Report Form (See Appendix 3: IP Temperature Excursion Report).
8. Connect the USB plug to your computer. The TempTale device will automatically begin creating the temperature report. The files will appear on your computer.

9. Dispose of the TempTale(s) in accordance with local and institutional policies and regulations regarding the disposal of electronic devices containing batteries. If a temperature excursion was reported, the TempTale should only be disposed of after approval of the excursion report is received from a Black Diamond Therapeutics representative.

10. File all relevant documentation and communication in the appropriate section(s) of your Pharmacy Binder or specified location.

See Appendix 4: Temptale Inspection Instructions for more information.

5. QUARANTINE

Conditions that warrant placement into quarantine include, but are not limited to:

- Potentially compromised bottles
- Suspected temperature excursions

To quarantine the IP, place it into a separate area of a limited access refrigerator (locked refrigerator or refrigerator in locked area) at 2-8 °C (36-46 °F), this area should be evident that it is the quarantine area, and the product is not for use. **DO NOT FREEZE.**

Please ensure temperature logs are maintained under quarantine.

Any time IP is placed into quarantine, the site pharmacist or designee is required to update the accountability log and remove the bottles from inventory.

If IP was placed in quarantine due to a temperature excursion, a Black Diamond Therapeutics representative will notify you if and when the IP is approved to be put back in inventory. Do not use quarantined bottles until Black Diamond Therapeutics clears them for use.

6. STORAGE

- BDTX-1535 should be stored at 2-8 °C (36-46 °F) in a locked refrigerator (or refrigerator within a locked room) with 24-hour temperature tracking and a temperature log.
  
  - Note: Transport to subject’s home at room temperature is OK although the subject should be instructed to store refrigerated while at home.

- Copies of the temperature log will be collected by the CRA.
- IP should not be used beyond expiration date.
- Only authorized study personnel should have access to the IP
• It is recommended that you prepare and use the IP in accordance with the First In, First Out (FIFO) method.

7. TEMPERATURE EXCURSIONS

A temperature excursion is when the temperature of the container storing the study drug product falls outside of the following range: 2-8 °C (36-46 °F).

The recorded readings should be rounded to nearest whole number. For example, 8.1 should be rounded to 8 (no excursion) and 8.5 should be rounded to 9 (temperature excursion), similarly on the lower limit 1.4 should be rounded to 1 (temp excursion) and 1.5 should be rounded to 2 (no temperature excursion).

The site is responsible for reporting shipment and storage temperature excursions per the instructions on the Temperature Excursion Report Form (See Appendix 3: IP Temperature Excursion Report). If a potential temperature excursion occurs (e.g., if the shipment is delayed for an extended period of time or if the storage refrigerator temperature is out of range), complete the Temperature Excursion Report Form per the instructions and notify your CRA immediately. Quarantine the potentially compromised bottles and do not use them until further instructions are provided.

8. DISPENSING

Subjects should be dispensed full bottle(s) of BDTX 1535 to cover one cycle of treatment at a time. Each bottle contains 30 capsules, appropriate number of bottles needed should be assigned to a subject in which the supplied amount is enough to cover a patient between visits with 2 additional days in case there is a delay in scheduling the next visit. Subjects should be instructed to complete the Dosing Diary every day to include the date and time capsules taken, number of capsules taken and/or the reason no capsules were taken. The Dosing Diary should be inspected at each clinic visit to ensure compliance. At the end of each treatment cycle, any unused capsules should remain in the bottle and be returned to the pharmacy. New bottle(s) should be dispensed for each cycle of treatment. Unused IP bottles should not be rolled over or re-used for another subject.

<table>
<thead>
<tr>
<th>Monotherapy Dispensing Chart (21-Day Cycles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
</tbody>
</table>
Note: For patients in the Food Effect Cohort, 1 bottle should be dispensed for Cycle 0. Note: Patients should continue to take capsules from their current bottle until the next cycle bottle is dispensed.

8.1. Prescription Form Completion

The local prescription form will be completed per Institutional practice and a copy of the request should be retained in the study files.

9. ACCOUNTABILITY

The Pharmacist or designee responsible should document each dispensed bottle of IP accountability log. (Appendix 4: Investigational Product Accountability Log).

- Note – site templates may be used for tracking site/subject inventory as long as all required fields are present.

Paper accountability forms will be used to track site inventory and by subject inventory.

The patient is expected to bring any unused study drug, any empty IP bottles, and their Dosing Diary to each study visit. The pharmacist will collect the study drug/bottles, complete a pill count, and document the IP accountability accordingly.

At the conclusion of the study, the CRA will complete final IP reconciliation and review your accountability records to approve for destruction or return. Destruction or return can only occur after obtaining written approval by the CRA and a Black Diamond Therapeutics representative. Your site must also have a destruction SOP that has been reviewed. All IP should remain on site until approval has been received for return or destruction. The site will provide a copy of final IP documents for CRA to review.

IP destruction or return must be documented by the site pharmacist or designee.

9.1. Return Process

US sites, if your site does not have a suitable destruction SOP, IP may also be returned to PCI Pharma Services in the US. Contact 1535drugsupplymanagement@bdtx.com for further instructions.

South Korean sites are to return all IP to Zuellig Pharma for destruction.

All relevant documentation should also be filed in your site Pharmacy binder.
**APPENDIX 1: IP REQUEST FORM TEMPLATE (US/S. KOREA)**

| Completion Instructions | Please place order for IP resupply at least 5 business days before the IP is needed on site to allow for processing, deliveries, and delays.  
| | Complete the below form, email with the subject line “BDTX-1535-101 Site ###: IP Request” to 1535drugsupplymanagement@bdtx.com and include your site CRA. |

<table>
<thead>
<tr>
<th>Site and Study Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protocol Number:</strong> BDTX-1535-101</td>
<td><strong>Site Number:</strong></td>
</tr>
<tr>
<td><strong>Type of Shipment Request:</strong></td>
<td><strong>Date Needed on Site:</strong></td>
</tr>
<tr>
<td>☐ Initial ☐ Resupply ☐ Emergency</td>
<td></td>
</tr>
<tr>
<td><strong>Shipping Address:</strong></td>
<td></td>
</tr>
<tr>
<td>Email:</td>
<td>Phone:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IP Request</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IP:</strong> ☐ BDTX- 25 mg (30 capsules/bottle)</td>
<td># of bottles requested:</td>
</tr>
<tr>
<td>☐ BDTX- 100 mg (30 capsules/bottle)</td>
<td># of bottles requested:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Requestor Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Requested by:</strong></td>
<td><strong>Signature and Date:</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BDTX Approval</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lot # Issued:</strong></td>
<td><strong># Bottles Issued:</strong></td>
</tr>
</tbody>
</table>

Please note any changes to the request:

<table>
<thead>
<tr>
<th>Name and Title</th>
<th>Name and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Signature and Date</strong></td>
<td><strong>Signature and Date</strong></td>
</tr>
</tbody>
</table>

**CLINICAL COMPLIANCE STATEMENT:** All required documentation for this site has been received and reviewed as complete and acceptable prior to initiation of the first shipment.
**APPENDIX 2: IP TEMPERATURE EXCURSION REPORT**

<table>
<thead>
<tr>
<th>Completion Instructions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>In the event of any temperature excursions noted in the transit or storage of the Investigational Product (IP), submit this form and a copy of the relevant IP Temperature Log(s) to <a href="mailto:tempexcursions@bdtherapeutics.com">tempexcursions@bdtherapeutics.com</a> within 1 working day of becoming aware of the temperature excursion.</td>
<td></td>
</tr>
<tr>
<td>IP should not be used until Black Diamond has provided approval that the drug is acceptable for use.</td>
<td></td>
</tr>
<tr>
<td>Submit this completed form together with the IP Storage Temperature Logs and packing slip if applicable</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study #</th>
<th>BDTX-1535-101</th>
<th>Product</th>
<th>BDTX-1535</th>
<th>Site #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temperature Excursion Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- □ In Transit
- □ In Storage

Location Address (if applicable):

<table>
<thead>
<tr>
<th>Reported By</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
</table>

**Immediate Action**

Has the IP been physically quarantined, according to the temperature range on the IP label?
- □ Yes  □ No

Has the IP been moved to quarantine per the accountability log?  □ Yes  □ No

**Details of Temperature Excursion**

<table>
<thead>
<tr>
<th>Shipment ID</th>
<th>□ N/A</th>
</tr>
</thead>
</table>

If shipment contained multiple boxes, list the Treatment Bottle number(s) associated with the temperature excursion:

**Probable cause(s) for temperature excursions:**

- □ Shipment delayed
- □ Power outage
- □ Packaging opened/ damaged on receipt
- □ Site maintenance of temperature equipment
- □ Temperature monitoring device error
- □ Other: Click or tap here to enter text.

If site does not have printable temperature read outs, how often is temperature monitored? Click or tap here to enter text.

If there is not a printable readout, please provide estimated time out of range storage, lowest/highest temperature noted: Click or tap here to enter text.

Is the last temperature data point for this temperature excursion outside the acceptable range for this IP? □ Yes  □ No

**Sponsor Review**

- □ Quality of IP has not been compromised and may continue to be used in the clinical trial. Please update the accountability log and return to inventory.
☐ IP is **not approved for further use** and should be identified as “damaged”. If temperature excursion is reported by the site, retain damaged IP for the Sponsor.

**BDTX QA Approval**

Name/Title

________________________________________________________

Signature                        Date
APPENDIX 3: TEMPTALE INSPECTION INSTRUCTIONS

Starting a TempTale®-4USB Monitor
- Press the Start button (1 – 3 seconds) until the “Sun” start icon appears in the upper left corner of the display.
- The TempTale®-4USB will now begin to record data after the pre-programmed start-up delay period has passed.

Marking an important event (“Date Stamp”)
- The TempTale®-4USB monitors provide an option to “Date Stamp” or mark an important event at any time during the monitoring cycle. This mark will be visible as an arrow on the time-temperature graph and in tabular data when viewing the tabular data.
- To mark the data while the monitor is recording, press and release the “Start” button. The “Arrow” icon will appear temporarily in the lower left corner of the display and the temperature history information will appear on the display in the following order:
  1. Average temperature
  2. Highest temperature recorded
  3. Total time above high temperature limit
  4. Lowest temperature recorded
  5. Total time below low temperature limit

Alarming
When the TempTale®-4USB is exposed to a temperature outside a pre-programmed time and temperature limit threshold, an “Alarm Bell” icon will appear in the lower right corner of the display.

Stopping a TempTale®-4USB Monitor
Press and hold (1 to 3 seconds) the Stop button until the “Stop” icon appears in the upper right corner of the display. Inserting the USB plug into a USB port on the computer will also stop the monitor.

Displayed Information
- Recording
- Temperature data
- Stopped Recording
- Marked Point
- Limits Exceeded

Receiving a TempTale®-4USB Monitor
- Recover the TempTale®-4USB monitor and press the red stop button (1 – 3 seconds) to manually stop the unit. NOTE: If the monitor is not stopped manually, the TempTale®-USB will continue to record data until the monitor is plugged into a USB port on the computer or until the pre-programmed trip length is exceeded.
- Verify the “Stop” icon is visible on the display.

Retrieving TempTale®-4USB Monitor reports and data files
- Pull out the USB connector cable from the side of the TempTale®-4USB monitor and insert the plug into a USB port on the computer.
- The monitor will automatically begin creating the Adobe® PDF report and Sensitec .txt data file within the monitor.
- After the LED on the face of the monitor is green, the monitor has completed the report and data file generation. The files are now accessible as files on a “removable drive” as shown below. (Windows XP and Vista). Note: Do not remove the plug from the USB port on the computer until the LED on the face of the unit is green.

Managing and Viewing TempTale®-4USB Monitor Files
- If the computer has Adobe® PDF compatible reader software installed, the PDF report file containing the monitor information, summary statistics, and time-temperature data graph, can be opened and viewed by double clicking on the .pdf file icon.
- If the computer has Sensitec’s TempTale® Manager Desktop Software installed, the .txt data file containing the monitor information and time-temperature data can be opened and accessed by double clicking on the .txt file icon.
- Both the PDF and .txt files can be moved, copied, saved and/or attached to email as allowed by the computer operating system.
APPENDIX 4: INVESTIGATIONAL PRODUCT ACCOUNTABILITY LOG

<table>
<thead>
<tr>
<th>Investigational Site No.:</th>
<th>Investigational Product Name: BDTX-1535</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Name:</td>
<td>Pharmacy Address:</td>
</tr>
<tr>
<td>Principal Investigator Name:</td>
<td>Dose Form (oral, IV, etc.): oral</td>
</tr>
<tr>
<td>Protocol Number: BDTX-1535-101</td>
<td>Strength:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Line No.</th>
<th>Date</th>
<th>Subject ID</th>
<th>Cycle #</th>
<th>Total Daily Dose (mg)</th>
<th>Quantity (dispensed or received)</th>
<th>Balance</th>
<th>Lot/ Batch #</th>
<th>Expiration date (If app)</th>
<th>Recorder's Initials</th>
<th>For oral agents</th>
<th>CRA</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>06</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version 3.0, August 24-2022